AstraZeneca is trading 3.1% up today at £12,106, partially recovering from a sharp decline triggered by merger speculation with Bristol Myers Squibb.
- Shares previously fell approximately 9% to £11,500 on August 3, 2026, following reports of preliminary talks for a potential $400 billion tie-up.
- The initial selloff reflected investor anxiety regarding significant deal risks and the complex integration challenges associated with a transaction of this magnitude.